Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination

Induction of SARS-CoV-2 Spike Glycoprotein Antibodies in Saliva and Plasma in Response to a COVID-19 Infection, Systemic COVID-19 Vaccination, and the Combination of COVID-19 and Vaccination

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04842305

Enrollment

500

Registered

2021-04-13

Start date

2021-04-30

Completion date

2024-03-15

Last updated

2021-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

sars-cov-2 antibodies, saliva, mucosal immunity, vaccination, covid19, spike glycoprotein

Brief summary

The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 Spike Glycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated and Non-SARS-CoV-2 Infected, COVID-19 Convalescents, Persons Vaccinated With Pfizer-BioNTech BNT162b2, Moderna mRNA-1273 or AstraZeneca ChAdOx1 nCov-19 AZD1222 Vaccines, and Convalescent COVID-19 Patients That Have Subsequently Been Vaccinated. A Potential Difference in the Immunoglobulin Concentrations of the Pfizer-BioNTech BNT162b2 Vaccine, Moderna mRNA-1273 vaccine and the AstraZeneca ChAdOx1-S Vaccine Will be Uncovered. This Knowledge About the Mucosal Immunity Will be Important for Further Designing of Vaccine Strategies.

Interventions

DIAGNOSTIC_TESTBlood- and saliva tests

Measurement of SARS-CoV-2 spike glycoprotein RBD antibodies in plasma and saliva

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Written informed consent * Both Hospital staff as well as non-health care workers will be invited to participate

Exclusion criteria

* Individuals not fulfilling the inclusion criteria or declining blood or saliva collection. *

Design outcomes

Primary

Measure	Time frame	Description
Titer of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma	Between 21 and 200 days after infection/vaccination	Detection of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma in participants who have been infected with COVID-19, vaccinated with Pfizer-BioNTech/Moderna mRNA-1273/AstraZeneca or infected and vaccinated

Secondary

Measure	Time frame	Description
Titer of SARS-CoV-2 spike glycoprotein RBD antibodies in saliva and plasma	Between 21 and 200 days after vaccination	Comparison of SARS-CoV-2 spike glycoprotein RBD antibodies (in saliva and plasma) between participants vaccinated with Pfizer-BioNTech, Moderna mRNA-1273 and AstraZeneca

Contacts

Primary ContactLennart Friis-Hansen, Dr.med.

lennart.jan.friis-hansen@regionh.dk61145916

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026